Financial Performance - The company's operating revenue for Q3 2023 was ¥66,655,963.89, a decrease of 62.04% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2023 was -¥186,786,712.39, with a year-to-date loss of -¥515,105,766.43[5]. - Total operating revenue for the first three quarters of 2023 was CNY 377.70 million, a decrease of 21.4% compared to CNY 480.34 million in the same period of 2022[21]. - Net loss for the first three quarters of 2023 was CNY 515.11 million, compared to a net loss of CNY 242.81 million in the same period of 2022, representing a 112.5% increase in losses[22]. - The company reported a total comprehensive loss of CNY 517.51 million, compared to a loss of CNY 239.92 million in the previous year[23]. Research and Development - Research and development expenses totaled ¥183,797,416.51 in Q3 2023, representing an increase of 66.54% year-on-year[6]. - The ratio of R&D expenses to operating revenue reached 275.74% in Q3 2023, up by 212.89 percentage points compared to the previous year[6]. - Research and development expenses surged to CNY 509.80 million, a significant increase of 79.7% from CNY 283.59 million in the previous year[21]. Cash Flow and Liquidity - The net cash flow from operating activities for Q3 2023 was -¥157,018,881.89, reflecting significant cash outflow due to increased R&D spending[6]. - Cash flow from operating activities was CNY 420.71 million, an increase from CNY 374.83 million in the same period of 2022[25]. - The net cash flow from operating activities was -$480,074,664.80, compared to -$225,307,702.69 in the previous year, indicating a significant decline in operational cash generation[26]. - Cash outflows for operating activities totaled $976,436,608.52, significantly higher than $640,393,563.39 in the previous year, indicating increased operational costs[26]. Assets and Liabilities - Total assets at the end of Q3 2023 were ¥1,410,986,860.49, a decrease of 29.15% from the previous year[6]. - The equity attributable to shareholders decreased by 55.41% year-on-year, amounting to ¥416,428,799.61 at the end of Q3 2023[6]. - The company's total equity decreased to CNY 416.43 million from CNY 933.89 million, a decline of 55.5%[21]. - Total liabilities decreased to CNY 994.56 million from CNY 1,057.54 million year-on-year, reflecting a reduction of 5.9%[21]. Cash and Cash Equivalents - Cash and cash equivalents dropped significantly from RMB 1,004,741,252.97 to RMB 414,106,845.46, a decline of approximately 58.8%[17]. - The total cash and cash equivalents at the end of the period were $385,356,845.46, a decrease from $1,004,741,252.97 at the beginning of the period[27]. Government Support - The company received government subsidies amounting to ¥28,017,741.77 during the reporting period, which are closely related to its normal business operations[8]. Future Guidance - The company has not provided specific guidance for future performance or new product developments in this report[15].

关于调整公司第四届董事会审计委员会委员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 四川百利天恒药业股份有限公司（以下简称"公司"）于 2023 年 10 月 27 日召开第四届董事会第九次会议，审议通过了《关于调整公司第四届董事会审计 委员会委员的议案》。现将有关情况公告如下： 证券代码：688506 证券简称：百利天恒 公告编号：2023-050 四川百利天恒药业股份有限公司 调整前： 杨敏（主任委员）、李明远、张苏娅 调整后： 杨敏（主任委员）、李明远、卓识 特此公告。 四川百利天恒药业股份有限公司董事会 2023 年 10 月 28 日 根据中国证券监督管理委员会发布的《上市公司独立董事管理办法》（2023 年 9 月 4 日起施行）有关规定，审计委员会成员应当为不在上市公司担任高级管 理人员的董事。根据上述规定，公司董事会对第四届董事会审计委员会委员进行 了调整，调整后公司董事、常务副总经理、董事会秘书、财务总监张苏娅女士不 再担任公司第四届董事会审计委员会委员。 为保障审计委员会的正常运行，根据《中华 ...

证券代码：688506 证券简称：百利天恒 四川百利天恒药业股份有限公司 投资者关系活动记录表 （2023年10月9日） □特定对象调研 □分析师会议 投资者关系活动 □媒体采访 √业绩说明会 类别 □新闻发布会 □路演活动 □现场参观 □其他（电话会议） 参与单位名称 参与公司 2023 年半年度业绩说明会的线上投资者 时间 2023年10月9日下午15:00-16:00 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http:// 地点 roadshow.sseinfo.com/） 董事长、总经理、首席科学官、核心技术人员：朱义先生 接待人员 董事、常务副总经理、财务总监、董事会秘书：张苏娅女士 独立董事：杨敏先生 投资者关系活动 1、请问公司有哪些中药中成药产品？在中药产业发展方向有什么 ...

证券代码：688506 证券简称：百利天恒 公告编号：2023-049 申请人：SystImmune,Inc. 适应症：非小细胞肺癌 四川百利天恒药业股份有限公司 自愿披露关于 SI-B001（EGFR×HER3 双特异性抗体） 联合多西他赛项目临床试验申请获得 FDA 批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，四川百利天恒药业股份有限公司（以下简称"公司"）自主研发的创新 生物药 SI-B001 联合多西他赛临床试验申请获得美国食品药品监督管理局（以下 简称"FDA"）批准，现将相关情况公告如下： 一、本次批准的基本情况 药品名称：SI-B001 联合多西他赛 申请编号：IND159724 四川百利天恒药业股份有限公司董事会 2023 年 10 月 9 日 审批结论：FDA 已对本品完成审评，同意本品开展的临床研究。 二、药品的基本信息 公司自主研发的 SI-B001 为 EGFR×HER3 双特异性抗体，通用名为 Izalontamab，是目前全球独家处于临床阶段的、可同时靶向 EGFR 和 H ...

安信证券股份有限公司 关于四川百利天恒药业股份有限公司 使用部分闲置募集资金暂时补充流动资金的核查意见 一、前次用于暂时补充流动资金的闲置募集资金的具体情况 公司于 2023 年 1 月 13 日分别召开第四届董事会第三次会议、第四届监事会 第二次会议，审议通过了《关于使用部分闲置募集资金暂时补充流动资金的议 案》，同意公司使用部分闲置募集资金暂时补充流动资金，总额不超过人民币 26,000 万元，使用期限自第四届董事会第三次会议审议批准之日起不超过 12 个 月。具体内容详见公司于 2023 年 1 月 16 日在上海证券交易所网站 （www.sse.com.cn）披露的《四川百利天恒药业股份有限公司关于使用部分闲置 募集资金暂时补充流动资金的公告》（公告编号：2023-006）。截至本核查意见披 露日，该笔募集资金暂时补充流动资金的使用期限尚未到期，不存在到期未归还 募集资金的情形。 二、募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意四川百利天恒药业股份有限 公司首次公开发行股票注册的批复》（证监许可〔2022〕2969 号），公司向社会 公开发行人民币普通股 4,010 万股，每股面值人民 ...

我们认为：本次募集资金暂时补充流动资金，有利于解决公司暂时的流动资 金需求，提高募集资金使用效率，提升公司经营效益，符合股东和广大投资者利 益。公司本次使用部分闲置募集资金暂时补充流动资金将用于创新药研发以及其 他与主营业务相关的经营活动，不直接或间接安排用于新股配售、申购或用于股 票及其衍生品种、可转换公司债券等的交易，没有与募集资金投资项目的实施计 划相抵触，不影响募集资金投资项目的正常进行，不存在改变或变相改变募集资 金投向和损害股东利益的情形。综上，公司独立董事同意公司使用不超过 10,000 万元暂时闲置募集资金用于补充流动资金，使用期限自本次董事会审议通过之日 起不超过 12 个月。因此，我们一致同意该议案。 四川百利天恒药业股份有限公司 独立董事：李明远 俞雄 杨敏 2023 年 9 月 7 日 独立董事关于第四届董事会第八次会议 四川百利天恒药业股份有限公司（以下简称"公司"）于 2023 年 9 月 7 日 召开了第四届董事会第八次会议。根据有关法律、法规、规章、规范性文件及《公 司章程》的规定，我们作为公司的独立董事，在仔细审阅了第四届董事会第八次 会议的相关文件后，经审慎分析，发表如下独 ...

四川百利天恒药业股份有限公司 关于使用部分闲置募集资金暂时补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 四川百利天恒药业股份有限公司（以下简称"公司"）于 2023 年 9 月 7 日召 开第四届董事会第八次会议、第四届监事会第八次会议审议通过了《关于使用部 分闲置募集资金暂时补充流动资金的议案》，同意公司使用部分闲置募集资金暂 时补充流动资金，总额不超过人民币 10,000 万元，将用于创新药研发以及其他 与主营业务相关的生产经营活动。补充流动资金的使用期限自本次董事会审议批 准之日起不超过 12 个月，到期将归还至募集资金专户。 公司独立董事、监事会发表了明确同意的意见，保荐机构安信证券股份有限 公司（以下简称"保荐机构"）出具了无异议的核查意见。现将相关情况公告如 下： 一、前次用于暂时补充流动资金的闲置募集资金的具体情况 公司于 2023 年 1 月 13 日分别召开第四届董事会第三次会议、第四届监事会 第二次会议，审议通过了《关于使用部分闲置募集资金暂时补充流动资金的议案》， 同意公司使用部 ...

2023 年 9 月 7 日，四川百利天恒药业股份有限公司第四届监事会第八次会 议在公司会议室召开。本次会议以现场及通讯表决方式召开，应出席监事 3 名， 实际出席监事 3 名，会议由监事会主席汪捷女士主持。本次会议的通知于 2023 年 9 月 2 日通过书面形式送达全体监事。本次会议的召集和召开程序符合《中华 人民共和国公司法》和《公司章程》的规定，会议决议合法、有效。 二、监事会会议审议情况 全体监事对本次监事会会议议案进行了审议，经表决形成如下决议： 1、《关于使用部分闲置募集资金暂时补充流动资金的议案》 监事会认为：公司本次拟使用闲置募集资金暂时补充流动资金履行了必要的 程序，符合《上海证券交易所科创板股票上市规则》《上市公司监管指引第 2 号 ——上市公司募集资金管理和使用的监管要求》《上海证券交易所科创板上市公 司自律监管指引第 1 号——规范运作》等有关法律、法规、规范性文件的相关规 定。公司本次将部分闲置募集资金用于暂时补充流动资金，充分考虑了公司的业 务发展规划，有利于提高募集资金的使用效率，降低公司财务费用，具有必要性 和合理性，不存改变或变相改变募集资金用途和损害股东利益的情形，符合公 ...

Financial Performance - The company reported a total revenue of 500 million CNY for the first half of 2023, representing a 15% increase compared to the same period last year[1]. - The company's operating revenue for the first half of 2023 was approximately ¥311.04 million, representing a 2.06% increase compared to the same period last year[14]. - The net profit attributable to shareholders of the listed company was approximately -¥328.32 million, a significant decline from -¥137.70 million in the previous year[14]. - The net cash flow from operating activities was approximately -¥323.06 million, compared to -¥148.16 million in the same period last year[14]. - The net profit attributable to shareholders was -328.32 million yuan, a decrease of 19.06 million yuan compared to the same period last year, primarily due to a decline in gross margin and a significant increase in R&D expenses[15]. - The basic earnings per share for the reporting period was -0.82 yuan/share, down 0.44 yuan/share from the same period last year, mainly due to the decrease in net profit[15]. - Operating costs rose to CNY 112.30 million, reflecting a significant increase of 29.79% compared to the previous year[109]. - Cash and cash equivalents decreased by 37.02% to CNY 632.76 million, primarily due to cash usage for R&D activities[112]. Research and Development - Research and development expenses increased by 25%, totaling 50 million CNY, focusing on new drug formulations[1]. - R&D expenses accounted for 107.00% of operating revenue, an increase of 50.16 percentage points compared to the same period last year, driven by ongoing clinical progress and increased R&D costs[15]. - The company achieved a total investment of $1,716.39 million in the development of the new product, Dexmedetomidine Hydrochloride Injection, with a recent approval for 20ml in June 2023 and for 50ml and 100ml in August 2023[24]. - The company has invested a total of $1,179.65 million in the development of Etomidate Emulsion Injection, which is currently under application for market approval[27]. - The company has increased its R&D personnel and clinical trial investments, contributing to the significant rise in R&D expenditures[66]. - The company is actively pursuing innovative research and development in the field of new antibody technologies for major diseases with urgent clinical needs[28]. - The company has established four core technology platforms for innovative biopharmaceuticals, with 426 invention patents applied globally, of which 91 have been authorized[80]. Product Development and Market Strategy - New product launches include two innovative drugs, projected to contribute an additional 100 million CNY in revenue by the end of 2023[1]. - The company is expanding its market presence in Southeast Asia, targeting a 5% market share by the end of 2024[1]. - The management highlighted a strategic shift towards digital marketing, aiming to increase online sales by 30% in the next year[1]. - The company aims to launch multiple new products classified as Category 3 and Category 4 pharmaceuticals, enhancing its product portfolio and market presence[24][26][30]. - The company is focusing on expanding its product line in the anesthetics and analgesics market, with several products in the pipeline[59]. - The company is focused on developing ADC drugs targeting TROP2 and HER2, both currently in Phase Ib clinical research, showing strong efficacy signals[81]. Clinical Trials and Approvals - The company has made significant advancements in its clinical trials, including the approval of multiple new drug applications and clinical trial notifications for innovative biopharmaceuticals throughout 2023[19][20]. - The dual-specific antibody SI-B001 has completed the first subject enrollment in Phase III clinical trials, making it the fastest progressing dual-specific antibody globally targeting EGFR×HER3[81]. - The company has received 8 marketing approvals and 5 clinical trial approvals during the reporting period[63]. - The company is currently conducting clinical trials for multiple projects, including SI-B001 and SI-B003, with total expected investments of ¥16,000,000 and ¥7,920,000 respectively[67]. Market Trends and Industry Outlook - The global pharmaceutical market size increased from $1,208.4 billion in 2017 to $1,401.2 billion in 2021, with a projected growth to $1,718.8 billion by 2025 and $2,114.8 billion by 2030, reflecting a compound annual growth rate (CAGR) of 5.2% and 4.2% respectively[34]. - The global oncology drug market grew from $93.7 billion in 2016 to $150.3 billion in 2020, with an expected increase to $304.8 billion by 2025 and $482.5 billion by 2030, indicating a CAGR of 12.5% from 2016 to 2020, 15.2% from 2020 to 2025, and 9.6% from 2025 to 2030[38][39]. - The Chinese chemical drug market is expected to grow from ¥722.6 billion in 2016 to ¥1,243.5 billion by 2030, with a CAGR of 3.95%[41]. Risk Factors and Challenges - Risk factors include regulatory changes and market competition, which the company is actively monitoring[1]. - The company faces risks related to ongoing losses, potential declines in revenue from key products, and the need for substantial future R&D investments[101]. - The pharmaceutical industry faces high regulatory barriers, requiring compliance with local regulations such as EMA and FDA approvals for market entry[46]. Environmental and Compliance Measures - The company has implemented strict environmental protection measures, ensuring that wastewater discharge meets national standards[123]. - The company has established a mechanism for environmental protection and complies with relevant laws and regulations[121]. - The company maintained a 100% pass rate for product quality control and market sampling inspections during the reporting period[97]. Shareholder and Governance - The company's major shareholders, including the actual controller Zhu Yi, have committed to a 36-month lock-up period for their shares post-IPO[138]. - The company has established a commitment to not reduce shareholdings for three full accounting years if it is not profitable post-IPO[139]. - The controlling shareholder has committed to uphold the rights of all shareholders and will not interfere with the company's management[157].

证券代码：688506 证券简称：百利天恒 公告编号：2023-041 四川百利天恒药业股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2023 年 6 月 14 日（星期三）下午 15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动。 投资者可于 2023 年 6 月 7 日（星期三）至 6 月 13 日(星期二)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@baili-pharm.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 四川百利天恒药业股份有限公司（以下简称"公司"）已于 2023 年 4 月 29 日发布公司 2022 年年度报告暨 2023 年第一季度报告，为便于广大投资者更全面 ...